"We are confident that the addition of these therapies to our portfolio will ultimately advance patient care in ways that could not be realized by either company alone, while also allowing us to realize substantial revenue and cost synergies and provide a strong return for investors.". ii American Cancer Society. Boston Scientific will host a conference call to discuss this transaction today, Tuesday, November 20, at 7:15 am ET. Conference Call and Webcast Information The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney and other cancers. The British Technology Group came under mounting pressure to dispose of all of its holdings to private companies as soon as it was commercially feasible. (LSE: BTG… On a GAAP basis, the transaction is expected to be dilutive in 2019, and less dilutive or increasingly accretive thereafter, as the case may be, due to amortization expense and acquisition-related net charges. BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG is an international surgical device manufacturer that develops and commercialises products that are used in minimally-invasive surgical procedures for treating liver cancer, emphysema and vascular diseases, specialty pharmaceuticals for acute care, and licensing business. BOTHELL, Washington, 14 December 2017 BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched. Discover how we serve a healthcare professionals and patients with a wide array of products, services and solutions. The acquisition of BTG by Boston Scientific (the "Acquisition") is intended to be implemented by way of a U.K. scheme of arrangement (the "Scheme"), pursuant to the terms of a Scheme Document, which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. BTG plc is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. Boston Scientific Corp. has agreed to buy British health-care firm BTG PLC for £3.3 billion ($4.24 billion), bolstering its presence in the growing field of interventional medicine. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. British Technology Group acquired the commercialisation rights to magnetic resonance imaging (MRI) under a revenue share scheme. • BTG platform technologies (TheraSphere™, Galil) enable BSX to continue to expand treatment options for cancer patients worldwide • BTG Acute Care Specialty Pharma franchise is a differentiated, profitable business along with cash generating Licensing assets • Immediately $0.02-$0.03 accretive to BSX 2019 adjusted EPS*; more so thereafter (508) 683-5543 Healthcare Professionals. The company has 1,600 employees globally, located in North America, Europe, Asia and Australia. The National Research Development Corporation officially came into being. In particular, the ability of persons who are not resident in the U.K. to vote their BTG shares with respect to the Scheme at the court meeting or with respect to any required resolutions at the general meeting, or to execute and deliver forms of proxy appointing another to vote at the court meeting and/or general meeting on their behalf, may be affected by the laws of the relevant jurisdictions in which they are located. Boston Scientific Corporation Website , BTG plc BTG is an international surgical device manufacturer that develops and commercialises products that are used in minimally-invasive surgical procedures for treating liver cancer, emphysema and vascular diseases, specialty pharmaceuticals for acute care, and licensing business. Featured stories and the latest news on what it takes to advance science for life. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.